Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 3071-3073

  Hu, Miao ^a   Lui, Sandra S H ^a   Ko, Gary T C ^b   Tomlinson, Brian ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atorvastatin; Ethnic difference; LDL cholesterol; Rosuvastatin

Indexed keywords

ARGININE; ATORVASTATIN; CYTOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ABCG2 GENE; ALLELE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUCASIAN; CHINESE; COMPARATIVE STUDY; DNA POLYMORPHISM; DRUG EFFICACY; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE SYSTEM; HONG KONG; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LETTER; LIPID ANALYSIS; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH SERVICE; OPEN STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ATORVASTATIN; ETHNIC DIFFERENCE; LDL-CHOLESTEROL; ROSUVASTATIN;

AGED; ANTICHOLESTEREMIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HONG KONG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 84885602904     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.04.091     Document Type: Article

References (10)

1. J.R. Zhu, B. Tomlinson, Y.M. Ro, K.H. Sim, Y.T. Lee, and C. Sriratanasathavorn A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study) Curr Med Res Opin 23 2007 3055 3068
2. A. Middleton, A.S. Binbrek, F.A. Fonseca, W. Wilpshaar, C. Watkins, and T.E. Strandberg Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis Curr Med Res Opin 22 2006 1181 1191
3. S.J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P.J. Barter Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am J Cardiol 105 2010 69 76
4. E. Lee, S. Ryan, and B. Birmingham Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 2005 330 341
5. B.K. Birmingham, C.T. Azumaya, C. Wei, Y. Chen, and R. Mosqueda-Garcia Increased exposure levels of rosuvastatin, atorvastatin and simvastatin in Chinese and Japanese subjects: a class effect? Clin Pharmacol Ther 83 2008 S15
6. W. Zhang, B.N. Yu, and Y.J. He Role of BCRP 421C > A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males Clin Chim Acta 373 2006 99 103
7. J.E. Keskitalo, O. Zolk, M.F. Fromm, K.J. Kurkinen, P.J. Neuvonen, and M. Niemi ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 86 2009 197 203
8. K.M. Bailey, S.P. Romaine, and B.M. Jackson Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 study Circ Cardiovasc Genet 3 2010 276 285
9. D.I. Chasman, F. Giulianini, J. MacFadyen, B.J. Barratt, F. Nyberg, and P.M. Ridker Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Circ Cardiovasc Genet 5 2012 257 264
10. B. Tomlinson, M. Hu, and V.W. Lee ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin Clin Pharmacol Ther 87 2010 558 562